The demand for products and services has been slashed, manufacturing disrupted and the supply chain is running out. The impact from the ongoing coronavirus outbreak in China is only starting to surface, with possible diversification of sourcing one key topic that has been thrown up for the global pharma industry.
'No Second China': EU Firms Face Coronavirus Fallout
The general economic and business impact on European firms from the coronavirus in China is widespread and severe, and companies must consider diversifying, warns an influential European trade group in a just-released business survey. But it concedes there are no China alternatives.

More from Strategy
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
More from Business
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.